BMC Endocrine Disorders

Table 2 Serum ALT, AST, TC and TG levels

From: α-NETA down-regulates CMKLR1 mRNA expression in ileum and prevents body weight gains collaborating with ERK inhibitor PD98059 in turn to alleviate hepatic steatosis in HFD-induced obese mice but no impact on ileal mucosal integrity and steatohepatitis progression

Group	ALT (U/L)	AST (U/L)	TC (mmol/L)	TG (mmol/L)
Group ND	57.00 ± 9.17 ^b	222.67 ± 22.55 ^a	3.17 ± 0.88 ^a	1.36 ± 0.09 ^b
Group NETA	144.76 ± 19.18	200.40 ± 73.26 ^a	8.29 ± 1.47	1.05 ± 0.17
Group PD	171.70 ± 89.29	468.30 ± 37.30	6.93 ± 0.13	1.08 ± 0.13
Group NETA + PD	79.59 ± 30.13 ^a	170.41 ± 56.78 ^a	7.58 ± 0.16	1.18 ± 0.02
Group HFD	202.00 ± 54.99	315.67 ± 25.70	6.83 ± 0.41	1.18 ± 0.02

ALT Alanine aminotransferase, AST Aspartate aminotransferase, TC Total cholesterol, TG Triglyceride
^aP < 0.05 vs group HFD
^bP < 0.01 vs group HFD

Back to article page

ISSN: 1472-6823

Contact us

General enquiries: journalsubmissions@springernature.com